Abstract
Epithelial ovarian cancer (EOC) is the most common histology of ovarian cancer defined as epithelial cancer derived from the ovaries, fallopian tubes, or primary peritoneum. It is the fifth most common cause of cancer-related death in women in the United States. Because of a lack of effective screening and non-specific symptoms, EOC is typically diagnosed at an advanced stage (FIGO stage III or IV) and approximately one third of patients have malignant ascites at initial presentation. The treatment of ovarian cancer consists of a combination of cytoreductive surgery and systemic chemotherapy. Despite the advances with new cytotoxic and targeted therapies, the five-year survival rate for all-stage EOC in the United States is 48.6%. Delivery of up-to-date guideline care and multidisciplinary team efforts are important drivers of overall survival. In this paper, we review our frontline management of EOC that relies on a multi-disciplinary approach drawing on clinical expertise and collaboration combined with community practice and cutting edge clinical and translational research. By optimizing partnerships through team medicine and clinical research, we combine our cancer center clinical expertise, community practice partnership, and clinical and translational research to understand the biology of this deadly disease, advance therapy and connect our patients with the optimal treatment that offers the best possible outcomes.
Highlights
Epithelial ovarian cancer (EOC) is the most common histology of ovarian cancer, defined as epithelial cancer derived from the ovaries, fallopian tubes, or primary peritoneum [1]
We review the frontline management of EOC and how we combine our cancer center clinical expertise, community practice partnership, and clinical and translational research to understand the biology of this deadly disease and advance therapy
Patients referred to COH from our community clinics for the surgical management of EOC are assessed by our gynecologic surgical oncologist team and we perform primary cytoreduction for EOC in selected patients followed by adjuvant chemotherapy
Summary
Epithelial ovarian cancer (EOC) is the most common histology of ovarian cancer, defined as epithelial cancer derived from the ovaries, fallopian tubes, or primary peritoneum [1]. It is the fifth most common cause of cancer-related death in women in the United States, with an estimated 21,750 new cases and 13,940 deaths in 2020 [2]. Its service area includes Los Angeles, San Bernadino, Riverside, and Orange Counties. COH delivers high quality cancer care to this sizable demographic through its large network of community oncology practice clinics in the area. We review the frontline management of EOC and how we combine our cancer center clinical expertise, community practice partnership, and clinical and translational research to understand the biology of this deadly disease and advance therapy
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
